Kornimate/medical-research-clean huggingface dataset:
effects of bowen's therapy and post isometric relaxation techniques in patients of temporomandibular joint disorder

Conditions: Temporomandibular Joint Disorders

Summary: the aim of this study to compare effects of bowen's therapy and post isometric relaxation techniques on pain, range of motions and function in patients with tmj disorder.

temporomandibular joint disorder is a very common and serious problem of mouth and face pain related condition that mostly effect in quality of life and compromise the daily functional activities of a patient. it can be caused by any trauma, biomechanical, neuromuscular and psychologically related problems. patient may come in acute and chronic phase. patient condition mostly vary and worsen day by day, it thoughts that tmjd going interval throw out the life span of patient. medicine, physical therapy interventions and surgical procedures are use in treatment of tmj disorder. this study will conducted the comparative effects of bowen's and post-isometric relaxation techniques on pain, rom and functions in tmj patients. the study would be randomized clinical trial. total 24 subjects will be assigned randomly into two groups by using lottery methods. baseline treatment will be same (ultrasound, tapping) in both groups. group a will be treated by bowen's therapy and group b will be treated by post-isometric relaxation technique for 30 min session (2 sessions/week and total 4 weeks). numeric pain rating scale, maximum mouth opening inter-incisal rural and jaw functional limitation scale-20 would be used as an outcome measurement tool for pain, range of motion and function respectively. measurement will be taken at baseline and at the end of the 4th week's treatment session. after assessing the normality data will be analyzed by using parametric / nonparametric test.

Eligibility criteria:
inclusion criteria: * male and female participant aged 20-50. * pain on function. * restricted jaw movement. * clicking, popping sound. * tenderness in muscle of mastication. * joint tenderness. * with a restricted mandibular range of motion 40mmor less measured interincisal. exclusion criteria: * systematic arthropathy such as. * rheumatoid arthritis * fracture of jaw or tmj. * malignant history of face and jaw. * prevent history of jaw or tmj surgery. * subject has/ had dental/ orthodontic treatment within the past 14 days

Keywords: temporomandibular disorder post isometric relaxation temporomandibular joint pain
a study of plazomicin compared with levofloxacin for the treatment of complicated urinary tract infection (cuti) and acute pyelonephritis (ap)

Conditions: Complicated Urinary Tract Infection; Acute Pyelonephritis

Summary: this was a multi-center, multi-national, double-blind, randomized, comparator-controlled study of plazomicin administered intravenously compared with levofloxacin, a standard approved intravenous therapy for complicated urinary tract infection (cuti) and acute pyelonephritis (ap).


Eligibility criteria:
key inclusion criteria: * documented or suspected cuti/ap with clinical signs and symptoms * normal kidney function defined as creatinine clearance (clcr) of ≥60ml/min using cockcroft-gault formula key exclusion criteria: * acute bacterial prostatis, orchitis, epididymitis, or chronic bacterial prostatis * gross heanaturia requiring intervention other than study drug * urinary tract surgery within 7 days of randomization or during the study period * a known nonrenal source of infection diagnosed within 7 days of randomization * a corrected qt interval \> 440 msec * history of hearing loss with onset before the age of 40 years, sensorineural hearing loss, or family history of hearing loss * pregnant or breastfeeding women

Keywords: urinary tract infection uti cuti pyelonephritis ap achn-490
nerve conduction block using transcutaneous electrical currents

Conditions: Nerve Block; Electric Stimulation

Summary: the purpose of this study is to determine whether the transcutaneous application of unmodulated high frequency alternating currents could produce a quickly conduction block of peripheral nerve.

in the last years several animal experimental studies have evidenced that high frequency unmodulated currents about 5 khz can cause a peripheral nerve block. however electric currents with these high frequencies that are usually used for the treatment of pain in humans are interrupted or modulated (i.e. interferential currents). it has show that the diameter of the nerve it is related with the frequency to produce the conduction block. for this reason the investigators decided to applied 20khz to observe the effects on maximal manual force and to compare versus sham stimulation. only one study has applied 5khz on experimental pain and they have demonstrated changes in somatosensory thresholds.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * neuromuscular disease. * epilepsy. * trauma, surgery or pain affecting the upper limb, shoulder girdle or cervical area. * osteosynthesis material in the upper limb. * diabetes. * cancer. * cardiovascular disease. * pacemaker or other implanted electrical device. * take any drug (nsaids, corticosteroids, antidepressants, analgesics, antiepileptics, ...) during the study and in the previous 7 days. * presence of tattoos or other external agent introduced into the treatment or assessment area. * pregnancy

Keywords: nerve conduction block high frequency stimulation handgrip
the moving 2 mindful (m2m) study: mindfulness group + ecological momentary intervention

Conditions: Anxiety; Stress

Summary: this study will evaluate the feasibility and acceptability of learning to breathe (a mindfulness intervention for adolescents) plus an ecological momentary intervention (learning to breathe plus), and will examine the extent to which mindfulness reduces dysregulated stress physiology, perceived stress, and anxiety in adolescents from high conflict homes.

adolescents from homes with interparental conflict will be randomly assigned to learning to breathe plus (the standard group program designed to increase mindfulness, plus a multi-method adaptive intervention that will be comprised of an ecological momentary intervention and online library of mindfulness practices) or to a health and wellness active control condition to determine feasibility, acceptability, and potential effectiveness of learning to breathe plus.

Eligibility criteria:
inclusion criteria: * two parents in the home * an adolescent who is between 14 and 18 years of age * marital distress and/or problematic interparental conflict (based on parent or youth reports) * youth reports of stress or anxiety exclusion criteria: * two parents in the home, but they are pursuing legal divorce or separation * parents are not willing to receive marital education/support * adolescents are severely clinically depressed or report suicidal ideation at baseline
pituitary down-regulation before ivf for women with endometriosis

Conditions: Fertility

Summary: endometriosis is a hormone dependent disease of women, in which endometrial tissue (the cells which line the uterus or womb) are found outside the uterus (womb). some women with endometriosis may be infertile. however, treatments for infertility such as in vitro fertilization (ivf) or ivf with intracytoplasmic sperm injection (ivf-icsi) appear to be less successful, i.e. the pregnancy rates are lower, for women with endometriosis than for women who may be infertile for other reasons. since endometriosis is hormone dependent, it has been suggested that suppressing the activity of hormones produced by the ovaries (which affect endometrial growth) may inactivate endometriosis and so increase the chances of pregnancy. recently it has been proposed that taking the oral contraceptive pill (ocp) for 6 to 8 weeks before ivf or ivf-icsi treatment could be used for this purpose. for our study, which is a randomised controlled trial, women with endometriosis meeting the study criteria planning to undergo ivf or ivf-icsi at the oxford fertility unit will be recruited. study participants will be randomised into 2 arms: experimental group and control group. the experimental group will be instructed to complete an 8 week course of ocp before beginning standard ivf treatment. the control group do not take any study medication before beginning standard ivf treatment. the ivf or ivf-icsi treatment for both groups is not altered by participation in the study. the aim of the study will be to determine if pretreatment with ocp improves ivf or ivf-icsi success rates, such as live birth and pregnancy rates, in patients who suffer from endometriosis. the study is funded by the oxford fertility unit.


Eligibility criteria:
inclusion criteria: participant is willing and able to give informed consent for participation in the study. * female aged 18 to 39 years old. * intending to undergo treatment with a first, second or third cycle of ivf or ivf-icsi. * diagnosed with any degree of endometriosis or endometrioma. * participants must meet world health organisation group 1 or 2 eligibility requirements for combined oral contraceptive use. exclusion criteria: the participant does not understand the english language, or has special communication needs. this is because it is impractical to provide, for this small scale study, information sheets and consent forms in other languages except english. * the patient has already undergone 3 or more ivf or ivf-icsi cycles. * patients who are already taking any medication to treat endometriosis such as progestins, ocp, gonadotrophin releasing hormone agonists, danazol, mirena, etc. or who have done so within the last 3 months. * participants who do not meet world health organisation group 1 or 2 eligibility requirements for combined oral contraceptive use.
study of janx007 in subjects with metastatic castration-resistant prostate cancer (engager-psma-01)

Conditions: Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer

Summary: this study is a first-in-human, phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (pk), pharmacodynamic (pd), and the preliminary efficacy of janx007 in adults with metastatic castration-resistant prostate cancer (mcrpc).


Eligibility criteria:
inclusion criteria: * male ≥18 years of age at the time of signing informed consent * histologically or cytologically confirmed adenocarcinoma of the prostate * for dose escalation and backfill: having mcrpc that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible * adequate organ function * for monotherapy expansion part a: have received ≤ 2 anti-androgen therapies in either the hspc or crpc setting and no more than 1 prior taxane regimen in the hspc or crpc setting. participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible. * for monotherapy expansion part b: have received ≤ 2 anti-androgen therapies in either the hspc or crpc settings * for monotherapy expansion part d: have received ≤ 1 anti-androgen therapy and a poly(adp-ribose) polymerase (parp) inhibitor for mcrpc and have progressed following treatment with the parp inhibitor * for combination expansion: have received ≤ 1 anti-androgen therapy other than darolutamide in the hspc setting and ≤ 1 taxane in the mcrpc setting. participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible. exclusion criteria: * prior solid organ transplant * prior treatment with psma-targeted car-t cell therapy or psma-cd3, psma-cd28 or other cd3 t-cell engaging bispecific antibodies or radioligand therapy * clinically significant cardiovascular disease * for monotherapy expansion part a: prior receipt of any treatment other than an arpi or taxane in the mcrpc setting * for monotherapy expansion part b: prior receipt of any treatment other than an anti-androgen therapy or prior receipt of a taxane containing regimen or more than 1 prior line of therapy for mcrpc * for monotherapy part d: more than 1 prior line of therapy for mcrpc or prior receipt of any treatment other than an anti-androgen therapy and parp inhibitor for mcrpc or prior receipt of a taxane in the mcrpc setting * for combination expansion: more than 1 prior line of therapy for mcrpc or prior receipt of any treatment other than a taxane for mcrpc or prior receipt of darolutamide or prior receipt of a taxane for hspc * active clinically significant infection (bacterial, viral, fungal, mycobacteria or other) * any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment

Keywords: prostate cancer castration-resistant prostate cancer
foot reflexology and abdominal massage

Conditions: Constipation

Summary: to determine and compare the effects of foot reflexology and abdominal massage applied to elderly individuals on constipation

this randomized controlled study examined the effects of foot reflexology and abdominal massage on constipation in 90 elderly individuals from three nursing homes. participants were divided into three groups: reflexology, abdominal massage, and control. the intervention groups received eight sessions over three weeks, while the control group received no treatment.

Eligibility criteria:
inclusion criteria: being 65 years or older having no movement restrictions not using pharmacological laxatives being diagnosed with constipation according to the roma iv criteria voluntarily agreeing to participate in the study exclusion criteria: individuals having a condition that prevents cognitive, affective and verbal communication having a disorder related to the nervous system and circulatory system having an injection applied to the abdominal region during the application process having a systematic disorder related to the gis (diarrhea, irritable bowel syndrome, fecal impaction, incontinence, etc.) having physiological and structural disorders that may prevent evacuation in the anus region (rectal fissure, etc.) having any negativity in the sensory function examination test performed with a sharp-blunt hard object on the sole of the foot and abdomen having any physiological and structural disorders related to the foot/sole of the foot

Keywords: constipation reflexology abdominal massage randomised
clinical performance of adhesive systems containing hema and 10-mdp in non carious cervical lesions

Conditions: Non Carious Cervical Lesion

Summary: the objective of this randomized, double-blind clinical trial is to evaluate the clinical performance of non-carious cervicals adhesive restorations using three self-etching adhesives containing hema and 10-mdp monomers.

sixty teeth (n = 20 for each group) will be randomized into 03 groups: clearfil se (contains mdp and hema), optibond all-inone (contains hema) and prime and bond universal (contains neither monomer) dispatch). restorations will be performed by a single operator, and no mechanical retention will be performed under the cavity. after 6, 12 and 24 months, the restorations will be evaluated by two calibrated examiners, using modified usphs criteria for retention (kappa = 1.00) and adaptation / marginal color (kappa = 0.81), and the results will be analysed by fisher and kruskal-wallis, respectively. an intragroup analysis will be performed using the cochran test (for retention) and wilcoxon (for marginal adaptation / staining).

Eligibility criteria:
inclusion criteria: * good oral hygiene * absence of periodontal disease * presence of at least 02 non-carious cervical lesions exclusion criteria: * presence of non-carious cervical lesion in non-vital teeth * occlusal instability * presence of orthodontic appliance * presence of removable partial dental prosthesis * high risk of caries (presence of three or more active caries lesions) * xerostomia * bruxism * patients allergic to base materials monomers * patients who do not accept the project conditions

Keywords: adhesives dental bonding
evaluation of efficacy of the prototype rpc (rapid pulse confirmation) device in detecting return of pulsatile flow in patients preparing to separate from cpb (cardiopulmonary bypass)

Conditions: Circulatory Failure; Cardiac Arrest

Summary: effective chest compressions are essential to survival in an arrest patient receiving cpr (cardiopulmonary resuscitation). a challenge in providing effective chest compressions is frequent interruption of compressions. a major cause of a recurrent interruption of chest compressions is pulse checks. pulse checks are difficult to quickly and accurately perform in the aha recommended time interval of under 10 seconds for reasons ranging from inexperience to body habitus. unnecessarily long pulse checks often delay reinitiating chest compressions leading to a fall in perfusion pressure to the coronary arteries lowering the chances of return of spontaneous circulation (rosc). to potentially solve the issues of evaluating the chest compression effectiveness and minimize the time interval of pulse checks, the authors have constructed a novel device that can be rapidly applied to an arresting patient and evaluate the current state of the circulatory system. the device is called the rapid pulse confirmation (rpc) device. it is designed to applied over a major artery (radial, ulnar, brachial, carotid, and femoral) and detect doppler shift of red blood cells to gauge red blood cell velocity and rate of pulsation. feasibility testing on the device was carried out using patients requiring cardiopulmonary bypass. arrest and return of spontaneous circulation during cardiopulmonary bypass is predictable and provided an ideal environment to test the initial performance of a device meant to detect return of spontaneous circulation. the primary working hypothesis was that there would be no significant difference in time of detection of rosc between the arterial line catheter and the rpc device at the end of cardiopulmonary bypass. the secondary hypothesis was that there would be no difference in pulse rate reading between the arterial line catheter and the rpc device.


Eligibility criteria:
inclusion: 1.18 or older 2.ef \>40% on pre-operative echocardiogram 3.patient with isolated cardiac valve disease to be repaired during scheduled surgery exclusion: 1.redo procedure 2.emergency procedure 3.peripheral vascular disease 4.previous cannulation or harvesting of radial artery 5.arterial stents in the radial, ulnar, brachial, femoral, or carotid arteries 6.history of peripheral arterial bypass 7.history of carotid artery stenosis 8.thoracic outlet syndrome 9.valvular heart disease not being repaired day of surgery 10.heart rhythm other than sinus prior to procedure (occasional pvc's ok) 11.patient refusal

Keywords: cardio pulmonary resuscitation pulse detection chest compressions
a study to evaluate the efficacy and safety of bimekizumab in adult korean study participants with moderate to severe plaque psoriasis

Conditions: Moderate to Severe Plaque Psoriasis

Summary: the purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.


Eligibility criteria:
inclusion criteria: * study participant must be at least 19 years of age at the time of signing the informed consent * study participant must be a korean adult with a diagnosis of moderate to severe psoriasis (pso) * study participant must have had plaque pso for at least 6 months prior to the screening visit * study participant must have psoriasis area and severity index (pasi) ≥12 and body surface area (bsa) affected by pso ≥10% and investigator's global assessment (iga) score ≥3 on a 5-point scale * study participant must be a candidate for systemic pso therapy and/or phototherapy * study participant agrees not to change their usual sun exposure during the course of the study and to use ultraviolet a/ultraviolet b sunscreens if unavoidable exposure occurs * a female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * not a female of childbearing potential (focbp) or a focbp who agrees to follow the contraceptive guidance during the treatment period and for at least 20 weeks after the last dose of study treatment exclusion criteria: * subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections * subject has concurrent acute or chronic viral hepatitis b or c or human immunodeficiency virus (hiv) infection * subject has known tuberculosis (tb) infection, is at high risk of acquiring tb infection, or has current or history of nontuberculous mycobacterium (ntmb) infection * subject has any active malignancy or history of malignancy within 5 years prior to the screening visit except treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer * study participant has a presence of active suicidal ideation or positive suicide behavior * study participant has a presence of moderately severe major depression or severe major depression * subject has a known hypersensitivity to any excipients of bimekizumab * subject has any other condition, including medical or psychiatric, which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study

Keywords: moderate to severe plaque psoriasis korean study participants bkz ucb4940
long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the primary objective of this study was to document the long-term safety and tolerability of teriflunomide in multiple sclerosis (ms) participants with relapse. the secondary objective was to document the long-term efficacy on disability progression, relapse rate and magnetic resonance imaging (mri) parameters.

participants completing the efc6049 (hmr1726d/3001) study were given the opportunity to continue in the extension study; * participants receiving teriflunomide 7 mg or 14 mg were blindly maintained on the same dose of teriflunomide. * participants receiving placebo were randomized at a 1:1 ratio to teriflunomide 7 mg or 14 mg. the study period per participant was broken down as follows: * double-blind treatment: up to a maximum of 288 weeks or until teriflunomide was commercially available in the country where participant lived, * post-washout follow-up: 4 weeks after last treatment intake. no post-washout follow up if participant continued on teriflunomide treatment by obtaining its commercial form after end of the study. the total duration of the extension was 292 weeks (about 6 years) from the first participant enrolled or until teriflunomide is commercially available in the country where participant lived.

Eligibility criteria:
inclusion criteria: * participant who completed the previous double-blind placebo-controlled study efc6049 and who did not meet criteria for treatment withdrawal. * willingness to participate in a long-term safety/efficacy trial. exclusion criteria: * any known condition or circumstance that would prevent in the investigator's opinion, compliance or completion of the study. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Keywords: multiple sclerosis oral treatment